By Adriano Marchese Shares of Liquidia were down in premarket trading on Thursday after it said that the U.S. Food and Drug Administration is still working.
MORRISVILLE, N.C., Jan. 25, 2024 Liquidia Corporation announced today that the U.S. Food and Drug Administration provided an update on its review of the New Drug Application for YUTREPIA™ .
Liquidia Technologies (LQDA) Provides Update on NDA for YUTREPIA streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
On January 25, 2024, the day following the proposed PDUFA goal date, Liquidia Corporation announced the FDA was still reviewing the NDA for pulmonary hypertension with interstitial lung disease for treprostinil inhalation powder (Yutrepia).
Liquidia (NASDAQ:LQDA) Stock Price Down 5% themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.